<DOC>
	<DOCNO>NCT01215929</DOCNO>
	<brief_summary>Methamphetamine use common US associate serious medical psychiatric problem . There also significant increase number patient enter treatment methamphetamine dependence , however , pharmacologic treatment identify effective treat methamphetamine addiction . Given withdrawal methamphetamine think contribute relapse methamphetamine use early treatment , important examine potential pharmacologic agent alleviate withdrawal . Thus , study design study methamphetamine withdrawal human . To end , 30 methamphetamine dependent participant ( age 18-65 year ) enter 4-week residential study . Urine sample obtain baseline ensure recent methamphetamine use . Intake assessment include cognitive testing , standardized assessment depression anxiety , profile mood state , methamphetamine selective severity assessment , methamphetamine withdrawal assessment , sleep quality quantity , pre-attentional measure attentional measure . Upon admission residential facility , study participant start ( 20-30mg ) long act amphetamine/d-amphetamine stabilize first 5 day . After stabilization participant randomize base sex , amphetamine withdrawal questionnaire score , methamphetamine selective severity assessment score either continue treatment amphetamine/d-amphetamine placebo 2 week . All subject place placebo last 7 day . The investigator hypothesis stop amphetamine administration methamphetamine dependent individual negatively impact mood , sleep cognitive function time-limited fashion may differ depend upon measure attentional , pre-attentional , measure adversely affect receive placebo compare maintain amphetamine .</brief_summary>
	<brief_title>Studying Amphetamine Withdrawal Humans</brief_title>
	<detailed_description />
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<criteria>2165 year old currently enrol treatment program history methamphetamine use recent use confirm positive urine toxicology screen amphetamine month prior study entry selfreported Methamphetamine use least 15 past 30 day use least one half gram methamphetamine per week month prior study entry woman childbearing age must negative pregnancy test enroll study current diagnosis alcohol , opiate , sedative physical dependence ill health ( e.g. , major cardiovascular , renal , endocrine , hepatic disorder ) history schizophrenia , bipolar type I disorder present recent use overthecounter prescription psychoactive drug drug ( ) would expect major interaction damphetamine medical contraindication receive study medication ( e.g. , previous adverse reaction damphetamine ) chronic pain condition ( due impact neurophysiological response current suicidality psychosis liver function test ( i.e. , liver enzymes ) great three time normal level pregnancy breastfeed child 1820 exclude P50 potential fully developed child adolescent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>methamphetamine withdrawal</keyword>
	<keyword>mood</keyword>
	<keyword>retention</keyword>
	<keyword>sleep</keyword>
</DOC>